Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Primary Progressive Multiple Sclerosis (PERSEUS)

NCT04458051 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT04458051
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04458051 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Primary Progressive Multiple Sclerosis (PERSEUS)
Lead sponsor
Sanofi
Phase
Phase 3
Overall status
Completed
Start date
August 13, 2020
Completion date
November 14, 2025
Enrollment
767 (actual)
Sites
277

Conditions

As the registry lists them; a condition with its own page is linked.

primary progressive multiple sclerosis